News

Press Releases Publications In the News

Intradigm Corporation Press Releases

• Intradigm Announces Allowance of Key RNA Interference (RNAi) Patent
  June 17, 2008
   
• Study Shows Intradigm’s RNAi Nanoplex Technology to Be Effective Systemic Sirna Delivery Platform for the Treatment of Various Cancer Models
  April 14, 2008
   
• Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property from University of Massachusetts Medical School
  April 9, 2008
   
• Intradigm Further Strengthens Competitive Position in RNA Interference (RNAi) Space by Licensing Key Delivery Intellectual Property from Massachusetts Institute of Technology
  January 29, 2008
   
• Intradigm Study Shows Ability of siRNAs Systemically Delivered with Targetran™ System to Suppress Tumor-Induced Angiogenesis in Mice
  October 24, 2007
  
  
• Intradigm selects Agilent Technologies as manufacturing partner for Novel RNA Interference Oncology Therapeutic
  June 26, 2007
  

• Intradigm announces addition of Samuel Zalipsky to management team
  May 30, 2007
  

• Intradigm announces significant enhancements of the company capabilities, a new series A financing and important addition to senior management team
  Nov. 21, 2006
  

• RNAi Therapeutic Successful for Treatment of SARS Respiratory Virus in Rhesus Macaque
  Sept. 12, 2005
  
  
• Intradigm Corporation Awarded National Eye Institute SBIR Funding For Treatment Of Ocular Neovascularization Diseases.  Jun. 21, 2004
  
  
• Intradigm Corporation Awarded National Cancer Institute STTR Funding For Brain Cancer. 
  Jun. 9, 2004
  
  
• Intradigm Corporation Awarded National Cancer Institute SBIR Funding For Tumor-Targeted siRNA Therapeutic.  May 20, 2004
  
  
• Intradigm's ICS-283: First Demonstration of Clinically Viable, Systemically Administered RNA Interference Therapeutic Agent for Cancer and Ocular Angiogenesis. Dec. 4, 2004
  
  
• QIAGEN (QGENF) And Intradigm Corporation Initiate Collaboration Targeting siRNA Applications.
  July 8, 2003